Amarantus Outlines LymPro Alzheimer’s Diagnostic Development Strategy

Amarantus Outlines LymPro Alzheimer’s Diagnostic Development Strategy
Filed under: dual diagnosis drug treatment

Thereafter the Company intends to gain U.S. clearance or approval for the test through the Food and Drug Administration‚Äôs de-novo Pre-market notification 510(k) or Premarket Approval (PMA) process which would represent a 3-month to 2-year process …
{Source}

Alexion's Manufacturing Concerns To Abate And Commercial Expansion To …
Filed under: dual diagnosis drug treatment

As focus shifts to Alexion's potential in the 2nd half of 2013, shares of the world's largest standalone orphan drug company are poised to outperform. … Soliris saw meaningful growth in the core markets of the United States, Western Europe, and Japan …
{Source}